Cost-Utility Analysis of Liraglutide in Type 2 Diabetes Patients in China after Chinese Reformation of Medical Care System

Journals Menu

Follow SCIRP

ISSN Print: 2327-5081
ISSN Online: 2327-509X
www.scirp.org/journal/jbm
E-mail: jbm@scirp.org

"Cost-Utility Analysis of Liraglutide in Type 2 Diabetes Patients in China after Chinese Reformation of Medical Care System"
written by Gaoyu Xie, Suning Zhao,
published by Journal of Biosciences and Medicines, Vol.6 No.12, 2018

has been cited by the following article(s):

No relevant information.

Follow SCIRP

[1]	Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus Diabetes Research and Clinical Practice, 2024 DOI:10.1016/j.diabres.2023.111034